Fuji Pharma Co.,Ltd. (4554.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenJPY 1,860.00

From 52W high−26.21%

Volume90800.00

Market capJPY 45.59B

P/E (TTM)15.7x

P/S (TTM)0.8x

Div yield2.49%

Key dataSep 18, 2026

Open

JPY 1,860.00

From 52W high

−26.21%

Volume

90800.00

Market cap

JPY 45.59B

ValuationView details →

P/E (Fwd)

22.0x

EV/EBITDA

5.8x

P/E (TTM)

15.7x

RSI (14)

58.4

MomentumView details →

1D Return

+2.53%

YTD Return

−1.64%

ValuationView details →

P/E (Fwd)

22.0x

P/E (TTM)

15.7x

EV/EBITDA

5.8x

EV/Sales

1.1x

P/S (TTM)

0.8x

P/B (TTM)

0.9x

ProfitabilityView details →

Gross Margin

36.24%

Net Margin

4.23%

EBITDA Margin

15.47%

ROE (TTM)

4.72%

ROA (TTM)

2.48%

Asset Turnover

0.59x

GrowthView details →

Revenue YoY

+17.31%

EPS YoY

−24.09%

FCF YoY

—

Revenue CAGR 3Y

+13.41%

EPS CAGR 3Y

+3.46%

EBITDA YoY

—

MomentumView details →

1D Return

+2.53%

YTD Return

−1.64%

1Y Return

+20.66%

RSI (14)

58.4

vs 50D SMA

+0.95%

vs 200D SMA

−9.72%

Capital & dividendView details →

Debt/Equity

0.43x

Current Ratio

1.68x

Quick Ratio

1.46x

Div Yield

2.49%

Div Rate

JPY 45.50

Div Growth 1Y

+7.06%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

54.57B

Net Income (TTM)

2.33B

Op. CF (TTM)

—

Next earningsNov 5, 2026 →

Latest newsMore news →

Fuji Pharma obtained manufacturing and marketing approval in Japan for two biosimilar products, ustekinumab BS 130mg intravenous infusion and golimumab BS 50mg subcutaneous autoinjector.2d ago

Fuji Pharma obtained manufacturing and marketing approval for a second biosimilar product in Japan.3d ago

Similar companies

Cuorips Inc.4894.T Daito Pharmaceutical Co.,Ltd.4577.T TAUNS Laboratories,Inc.197A.T Heartseed Inc.219A.T SEIKAGAKU CORPORATION4548.T ASKA Pharmaceutical Holdings Co.,Ltd.4886.T Find similar companies →

Latest newsMore news →

Fuji Pharma obtained manufacturing and marketing approval in Japan for two biosimilar products, ustekinumab BS 130mg intravenous infusion and golimumab BS 50mg subcutaneous autoinjector.2d ago Fuji Pharma obtained manufacturing and marketing approval for a second biosimilar product in Japan.3d ago Fuji Pharma announced on September 7, 2026, the launch of 'Fuji Evidence Digest', a new web content for healthcare professionals that delivers medical papers in audio format, featuring AI navigator 'Hotaru' and AI doctor 'Dr. Tateyama'.12d ago